scholarly journals An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours

2018 ◽  
Vol 103 ◽  
pp. 17-23 ◽  
Author(s):  
H.-T. Arkenau ◽  
A. Italiano ◽  
G. Mak ◽  
M. Toulmonde ◽  
R.D. Baird ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Solid Tumours ◽  
Extended Phase ◽  
Phase Ib ◽  
Orally Active ◽  
Her2 Tyrosine Kinase Inhibitor

scholarly journals Role of Hepatic Transporters in the Disposition and Hepatotoxicity of a HER2 Tyrosine Kinase Inhibitor CP-724,714

2009 ◽  
Vol 108 (2) ◽  
pp. 492-500 ◽  
Author(s):  
Bo Feng ◽  
Jinghai J. Xu ◽  
Yi-An Bi ◽  
Rouchelle Mireles ◽  
Ralph Davidson ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Hepatic Transporters ◽  
Her2 Tyrosine Kinase Inhibitor
Sign in / Sign up

Export Citation Format

Share Document